Compounds > atorvastatin
Page last updated: 2024-08-24

atorvastatin and Hyperchylomicronemia Late Onset

atorvastatin has been researched along with Hyperchylomicronemia Late Onset in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B1
Bruckert, E; Chapman, MJ; Foglietti, MJ; Giral, P; Jacob, N; Turpin, G1
Bairaktari, ET; Chatzidimou, KG; Elisaf, MS; Goudevenos, JA; Mikhailidis, DP; Milionis, HJ1
Aristegui, R; Chaves, J; Civeira, F; da Silva, PM; Díaz, C; Gómez-Gerique, JA; Hernández, A; Hernández, G; Lima, J; Mostaza, JM; Oliván, J; Pintó, X; Rodriguez-Botaro, A; Ros, E; Sol, JM; Vilardell, M; Zambón, D1
Achimastos, A; Bairaktari, E; Elisaf, M; Goudevenos, J; Kakafika, A; Liamis, G; Miltiadous, G; Tsimihodimos, V1

Trials

5 trial(s) available for atorvastatin and Hyperchylomicronemia Late Onset

ArticleYear
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:11

    Topics: Adipokines; Adiponectin; Adult; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Blood Glucose; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose Metabolism Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Leptin; Lipids; Male; Middle Aged; Poland; Pyrroles; Resistin; Risk Reduction Behavior; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha

2012
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
    Atherosclerosis, 2001, Feb-01, Volume: 154, Issue:2

    Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides

2001
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.
    Current medical research and opinion, 2001, Volume: 16, Issue:4

    Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Monitoring; Fasting; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type V; Lipids; Lipoprotein(a); Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome

2001
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
    Atherosclerosis, 2002, Volume: 162, Issue:2

    Topics: Adult; Atorvastatin; Bezafibrate; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides

2002
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
    Current medical research and opinion, 2002, Volume: 18, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clofibric Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome

2002